GEN Exclusives

More »

GEN News Highlights

More »
Sep 9, 2009

Otsuka Inks Six-Month Extension to Research Deal with MethylGene in Ocular Diseases

  • Otsuka Pharmaceutical has extended its research collaboration related to ocular diseases with MethylGene for an additional six months. Otsuka will provide $625,000 to fund research until the end of March 2010. The company will also make a $1.5 million equity investment in MethylGene by the end of October. The current agreement also allows Otsuka to further prolong the collaboration beyond this initial six-month period.

    The partnership, which has already resulted in lead compounds, will focus on identifying more leads and optimizing the molecules. MethylGene will continue to design, synthesize, characterize, and screen small molecule kinase inhibitors that treat ocular diseases excluding cancer. Otsuka will provide additional assistance in the scale-up of selected compounds and preclinical development in multiple in vivo settings for both efficacy and safety.

    The original alliance was formed in March 2008, and MethylGene received $2 million up front. Achievement of development, regulatory, commercialization, and sales milestones would trigger $50.5 million in additional payments. Otsuka remains solely responsible for the clinical development and global commercialization and will pay MethylGene royalties.


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

GEN Poll

More » Poll Results »

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?